Calidi Biotherapeutics Q2 FY26 net loss narrows 26.32% to $4.2 million; general and administrative expense drops 48% to $1.6 million
Reuters2026/08/13 20:37- Calidi Biotherapeutics posted a net loss attributable to common stockholders of USD 4.2 million, or USD 2.94 a share, in Q2 2026.
- Loss narrowed from USD 5.7 million a year earlier, while research and development expense held at USD 2.6 million.
- General and administrative expense fell 48% to USD 1.6 million, reflecting a USD 1.5 million reduction versus Q2 2025.
- Cash was USD 4.1 million at June 30, down from USD 5.6 million at Dec. 31, with USD 0.2 million restricted cash.
- FDA pre-IND feedback backed the CLD-401 strategy, with first patient dosing targeted for Q1 2027, CEO Eric Poma said.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
EdiliziAcrobatica announces shareholder meeting notice
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Crypto prices
More
